Table III.

Platelet transfusion responses within the two weeks before and after eculizumab administration.

	All patients (n = 10)	Responders (n = 4)	Non-responders (n = 6)	P⋆
Before eculizumab (N = 73 transfusions)
Pretransfusion PLT count (×109/l)	8·2 ± 5·2	7·8 ± 5·4	8·6 ± 50	0·72
I h post-transfusion PLT count (×109/l)	191 ± 15·3	20·9 ± 16·2	17·3 ± 14·3	0·25
Platelet increment (×109/l)	11 ± 14·5	13·2 ± 15·1	8·7 ± 13·7	0·22
Days to next transfusion	1·4 ± 1·3	1·4 ± 1·3	1·5 ± 1·3	0·85
After eculizumab (N = 88 transfusions)
Pretransfusion PLT count (×109/l)	9·5 ± 7·8	11·5 ± 9·9	8·8 ± 6·8	0·49
I h post-transfusion PLT count (×109/l)	22·9 ± 15·8	36·3 ± 16·6	18·1 ± 12·5	0·033
Platelet increment (×109/l)	13·8 ± 140	26·0 ± 17·3	9·4 ± 9·5	0·038
Days to next transfusion	1·7 ± 1·3	2·5 ± 1·3	1·4 ± 1·2	0·10

Data are given as mean ± SD. PLT, platelet.

To highlight it is statistically significant are bolded.

^⋆P value for comparing responders and non-responders (CCI criteria) using the linear mixed models to account for within-subject correlation.